despit
major
progress
prevent
treatment
infecti
diseas
particularli
develop
antibiot
vaccin
remain
second
lead
caus
death
worldwid
http
accord
world
health
organ
approxim
million
death
caus
infecti
diseas
http
furthermor
approxim
death
among
children
year
age
due
infecti
diseas
http
wwwwhointghochildhealthmortalitycausesen
emerg
new
infect
reemerg
known
infect
main
obstacl
way
toward
combat
infecti
diseas
emerg
infect
caus
zoonot
pathogen
approxim
caus
pathogen
deriv
wildlif
jone
et
al
contribut
factor
often
associ
human
activ
result
increas
human
exposur
anim
pathogen
http
wwwniaidnihgovtopicsemergingpagesintroductionaspx
exampl
chang
human
demograph
behaviour
caus
outbreak
chikungunya
viru
infect
tanzania
poliomyel
india
sever
acut
respiratori
syndrom
sar
china
chang
land
use
agricultur
industri
caus
outbreak
plagu
unit
state
european
enceph
norway
far
eastern
enceph
japan
nipah
viru
infect
malaysia
rift
valley
fever
egypt
jone
et
al
furthermor
excess
use
antimicrobi
agent
contribut
develop
strain
pathogen
mycobacterium
tuberculosi
plasmodium
falciparum
addit
human
activ
natur
genet
variat
recombin
adapt
known
pathogen
influenza
virus
result
appear
new
strain
epidem
pandem
potenti
besid
transmit
natur
infecti
diseas
also
emerg
via
intent
releas
dissemin
unmodifi
engin
form
pathogen
biolog
toxin
use
agent
biowarfar
bioterror
http
wwwniaidnihgovtopicsemerg
et
al
use
microb
product
bioweapon
long
histori
hilleman
poison
faecal
contamin
arrow
spear
punji
stick
practis
ancient
time
contamin
water
food
suppli
project
infect
anim
human
cadav
enemi
camp
releas
infect
rat
also
employ
later
centuri
begin
centuri
biolog
warfar
acquir
scientif
basi
exampl
base
discoveri
microbiolog
robert
koch
loui
pasteur
germani
infect
livestock
anim
feed
suppli
world
war
substanti
biolog
warfar
research
crop
anim
human
pathogen
toxin
conduct
countri
includ
germani
canada
unit
kingdom
japan
unit
state
ussr
world
war
ii
due
adopt
intern
biolog
weapon
convent
enter
forc
http
wwwopbworgconventiondocumentsbtwctextpdf
develop
product
stockpil
bacteriolog
weapon
prohibit
christoph
et
al
howev
effort
complet
stop
biolog
warfar
develop
exampl
iraq
began
extens
programm
pursu
product
weapon
bacillu
anthraci
clostridium
perfringen
wheat
rust
toxin
develop
deliveri
system
bioweapon
hilleman
therefor
remain
threat
bioterrorist
group
use
pathogen
attack
civilian
inde
seri
postal
mail
contain
b
anthraci
spore
unit
state
jernigan
et
al
risk
bioterror
remain
high
promot
signific
effort
toward
develop
diagnost
prophylact
therapeut
measur
biodef
http
vaccin
mainstay
infecti
diseas
prophylaxi
approv
unit
state
prevent
emerg
reemerg
bioterror
infect
target
popul
vaccin
vari
gener
popul
case
season
influenza
popul
live
travel
endem
area
case
yellow
fever
individu
high
risk
exposur
militari
personnel
major
approv
vaccin
infecti
diseas
base
live
attenu
kill
whole
pathogen
despit
demonstr
protect
efficaci
limit
safeti
major
issu
vaccin
exampl
vaccin
anthrax
base
protect
antigen
pa
b
anthraci
may
also
contain
compon
bacterium
lethal
factor
lf
oedema
factor
ef
therefor
composit
fulli
defin
vari
lot
lot
presenc
lf
ef
vaccin
may
caus
sever
allerg
reaction
includ
anaphylaxi
emerg
biosolut
addit
induc
protect
immun
administ
mani
five
dose
period
month
interv
thereaft
emerg
biosolut
similarli
vaccin
plagu
current
discontinu
base
yersinia
pesti
caus
seriou
side
effect
approxim
vaccin
individu
also
protect
pneumon
form
diseas
hassani
et
al
meyer
licens
smallpox
vaccin
gener
well
toler
howev
may
caus
seriou
side
effect
individu
immun
defici
skin
disord
http
wwwniaidnihgovtopicssmallpox
anoth
licens
vaccin
yellow
fever
rare
case
caus
enceph
neurolog
syndrom
moreov
vaccin
caus
sever
viscerotrop
diseas
similar
yf
result
activ
yf
viru
replic
genet
predispos
host
direct
viral
injuri
vital
organ
lindsey
et
al
addit
safeti
concern
tradit
vaccin
need
frequent
redesign
address
genet
variat
target
pathogen
strain
exampl
circul
influenza
virus
undergo
constant
antigen
drift
occasion
antigen
shift
http
wwwcdcgovfluaboutviruseschangehtm
mutat
may
occur
viru
strain
result
reduc
vaccin
efficaci
skowronski
et
al
case
season
trival
influenza
vaccin
prepar
first
vaccin
lot
new
influenza
season
take
month
date
vaccin
strain
select
matthew
overal
recent
emerg
new
infect
outbreak
exist
infect
threat
bioterror
attack
global
popul
underscor
urgent
need
robust
highli
scalabl
altern
manufactur
system
independ
propag
live
bacteria
virus
viru
strain
adapt
tradit
matric
egg
system
expect
capabl
produc
safe
effect
afford
vaccin
administ
dose
produc
high
quantiti
within
short
time
frame
provid
rapid
respons
subunit
vaccin
base
recombin
pathogen
protein
peptid
produc
heterolog
system
highli
promis
altern
whole
whole
vaccin
far
five
subunit
vaccin
licens
four
base
highli
purifi
particl
vlp
glaxosmithklin
recombivax
merck
hepat
b
viru
glaxosmithklin
merck
human
papillomaviru
besid
subunit
vaccin
human
monoclon
antibodi
antivir
agent
immun
modul
also
promis
prophylaxi
treatment
measur
control
emerg
infect
bishop
schleich
et
al
shurtleff
zhu
et
al
protein
prevent
reduc
sever
diseas
varieti
mechan
exampl
monoclon
antibodi
neutral
pathogen
growth
limit
spread
infect
adjac
cell
inhibit
biolog
activ
toxin
depend
size
structur
decor
target
recombin
protein
well
cost
consider
choic
heterolog
express
system
made
bacteria
yeast
insect
cell
mammalian
celik
chen
drugmand
et
al
zhu
product
platform
scalabl
flexibl
howev
certain
limit
associ
product
efficaci
safeti
respons
time
scalabl
cost
plant
long
propos
attract
platform
product
recombin
protein
human
health
perceiv
safeti
advantag
harbour
mammalian
pathogen
cost
scalabl
advantag
stainless
steel
ferment
requir
result
studi
conduct
last
two
decad
suggest
plant
highli
scalabl
safe
platform
product
subunit
vaccin
monoclon
antibodi
therapeut
protein
basaran
stoger
et
al
tiwari
et
al
twyman
et
al
xu
et
al
addit
plant
cell
capabl
perform
eukaryot
modif
ptm
target
protein
includ
glycosyl
substanti
similar
found
mammalian
cell
gomord
fay
howev
core
glycan
structur
share
mammalian
plant
glycan
termin
residu
differ
recombin
protein
contain
termin
bisect
core
sialic
acid
residu
bosch
et
al
gomord
et
al
webster
thoma
plant
mammal
also
differ
structur
glycan
contrast
glycan
synthes
stepwis
transfer
monosaccharid
endoplasm
reticulum
er
golgi
complex
mammalian
cell
synthes
glycan
plant
cell
produc
glycan
gomord
et
al
sever
studi
conduct
examin
potenti
neg
effect
glycan
safeti
efficaci
subunit
vaccin
therapeut
protein
exampl
glucocerebrosidas
produc
carrot
cell
cultur
taligluceras
alfa
compar
glucocerebrosidas
produc
chines
hamster
ovari
cell
line
variant
enzym
shown
structur
highli
homolog
display
compar
enzymat
activ
uptak
macrophag
furthermor
singl
intraven
administr
taligluceras
alfa
dose
mgkg
correspond
clinic
dose
caus
advers
reaction
clinic
patholog
find
icr
mice
shaaltiel
et
al
addit
allergen
human
assess
hemagglutinin
ha
vlp
influenza
vaccin
candid
carri
residu
termin
glcnac
could
potenti
induc
hypersensit
reaction
vaccin
individu
landri
et
al
serolog
analysi
demonstr
vlp
vaccin
significantli
increas
level
natur
occur
serum
igg
glycan
furthermor
subject
studi
detect
ige
respons
plant
glycan
vaccin
author
suggest
termin
glcnac
could
shield
proxim
residu
prevent
ige
mast
cellbasophil
degranul
landri
et
al
result
larger
human
studi
vaccin
demonstr
vaccin
subject
develop
ige
direct
mmxfmufx
motif
known
carbohydr
determin
subject
show
symptom
allergyhypersensit
ward
et
al
author
suggest
plant
igg
may
block
allerg
respons
vaccin
subject
contribut
allergen
desensit
ward
et
al
glycosyl
also
benefici
recombin
therapeut
protein
vaccin
antigen
exampl
unlik
glucocerebrosidas
produc
chines
hamster
ovari
cell
line
taligluceras
alfa
need
undergo
vitro
glycan
process
expos
termin
mannos
glycan
requir
enzym
uptak
via
macrophag
mannos
receptor
shaaltiel
et
al
plant
glycan
may
also
serv
glycoadjuv
mucos
vaccin
antigen
facilit
uptak
cell
gomord
et
al
howev
remain
concern
glycan
may
present
safeti
regulatori
issu
clinic
develop
pharmaceut
protein
due
potenti
immunogen
plant
glycoepitop
human
bosch
et
al
gomord
et
al
prevent
unwant
advers
effect
caus
glycan
engin
plant
gener
facilit
glycosyl
recombin
protein
bosch
et
al
gomord
et
al
webster
thoma
anoth
approach
elimin
glycan
recombin
protein
planta
deglycosyl
enzym
mamedov
et
al
altern
put
glycosyl
site
knock
mutagenesi
mett
et
al
strategi
target
gene
deliveri
protein
express
plant
includ
engin
transgen
transplastom
plant
base
stabl
integr
target
gene
host
nuclear
chloroplast
genom
respect
plant
system
transient
express
base
replic
recombin
plant
viral
vector
boost
nucleic
acid
templat
daniel
et
al
lico
et
al
rybicki
yusibov
et
al
transgen
plant
produc
recombin
protein
high
effici
requir
rel
long
develop
time
establish
produc
line
express
transgen
may
decreas
time
due
transcript
gene
silenc
matzk
et
al
transplastom
plant
contain
abund
copi
transgen
technolog
still
limit
rel
speci
limit
modif
chloroplast
daniel
et
al
verma
daniel
transient
express
approach
extens
use
allow
product
larg
quantiti
target
protein
within
short
time
frame
rybicki
particularli
attract
featur
case
pathogen
may
use
bioweapon
epidem
recombin
protein
produc
plant
system
reach
clinic
advanc
preclin
stage
develop
review
yusibov
et
al
yusibov
et
al
furthermor
two
product
receiv
regulatori
approv
veterinari
vaccin
newcastl
diseas
viru
poultri
produc
transgen
tobacco
plant
cell
suspens
dow
agrosci
llc
indianapoli
approv
us
depart
agricultur
center
veterinari
biolog
http
taligluceras
alfa
recombin
enzym
indic
treat
patient
gaucher
diseas
produc
suspens
cultur
transgen
carrot
plant
root
cell
line
protalix
biotherapeut
inc
carmiel
israel
approv
us
food
drug
administr
shaaltiel
et
al
traynor
order
plant
significantli
contribut
satisfi
global
demand
subunit
vaccin
monoclon
antibodi
antivir
therapeut
protein
establish
manufactur
facil
oper
complianc
current
good
manufactur
practic
cgmp
guidelin
requir
current
sever
plant
facil
alreadi
oper
north
america
eg
kentucki
bioprocess
owensboro
ky
calib
biotherapeut
bryan
tx
medicagomitsubishi
tanab
pharma
quebec
qc
canada
research
triangl
park
nc
fraunhof
usa
center
molecular
biotechnolog
newark
de
europ
eg
icon
geneticsnomad
bioscienc
gmbh
hall
germani
fraunhof
institut
molecular
biolog
appli
ecolog
aachen
germani
although
total
manufactur
capac
facil
quit
signific
eg
million
dose
influenza
vaccin
per
month
less
month
yusibov
et
al
establish
new
facil
worldwid
expans
exist
facil
like
requir
ensur
capabl
system
rapidli
respond
urgent
need
case
pandem
bioterror
threat
anthrax
seriou
infecti
diseas
caus
facult
anaerob
bacterium
b
anthraci
primari
categori
pathogen
brachman
kaufmann
koch
anthrax
zoonot
diseas
occur
human
exposur
infect
anim
anim
tissu
davi
van
ness
via
bioterror
http
wwwcdcgovanthraxbioterrorismindexhtml
inglesbi
et
al
jernigan
et
al
three
form
diseas
caus
b
anthraci
cutan
gastrointestin
inhal
anthrax
caus
inhal
aerosol
spore
sever
highest
mortal
rate
brachman
et
al
therefor
import
context
bioterror
princip
virul
factor
b
anthraci
pa
form
two
exotoxin
lethal
toxin
letx
oedema
toxin
via
bind
lf
ef
respect
enter
cytoplasm
lead
cell
death
young
collier
pa
elicit
specif
neutral
antibodi
correl
protect
immun
fowler
et
al
littl
et
al
pitt
et
al
weiss
et
al
major
target
anthrax
vaccin
develop
unit
state
approv
anthrax
vaccin
anthrax
vaccin
adsorb
base
pa
protein
prepar
filtrat
microaerophil
cultur
avirul
nonencapsul
strain
b
anthraci
formul
aluminum
hydroxid
adjuv
emerg
biosolut
achiev
full
protect
efficaci
administ
multipl
dose
mani
five
dose
period
month
year
interv
thereaft
may
caus
safeti
issu
due
variat
composit
emerg
biosolut
last
decad
signific
effort
made
toward
develop
oral
administ
vaccin
anthrax
initi
attempt
made
produc
anthrax
subunit
vaccin
candid
transgen
plant
tomato
potato
mustard
aziz
et
al
gorantala
et
al
exampl
pa
stabli
express
transgen
tobacco
plant
demonstr
cytotox
activ
similar
nativ
pa
vitro
total
solubl
protein
extract
transform
leav
ad
cell
combin
lf
aziz
et
al
immunogen
vaccin
candid
evalu
subsequ
express
transgen
tomato
plant
administ
intraperiton
total
solubl
protein
extract
transgen
tomato
leav
elicit
antibodi
mice
howev
transgen
express
level
well
titr
antibodi
rais
low
aziz
et
al
recent
attempt
made
develop
comprehens
oral
administ
vaccin
suitabl
veterinari
human
use
purpos
express
transgen
mustard
brassica
juncea
whose
leav
stem
consum
veget
human
use
feed
cattl
although
express
level
vitro
cytotox
vari
due
random
total
solubl
protein
transgen
b
juncea
adjuv
alhydrogel
cholera
toxin
ct
gener
signific
igg
titr
gorantala
et
al
signific
serum
iga
titr
faecal
secretori
iga
titr
also
detect
indic
develop
mucos
immun
respons
oral
immun
either
adjuv
nonadjuv
b
juncea
confer
surviv
mice
follow
lethal
intraperiton
anthrax
challeng
gorantala
et
al
anthrax
vaccin
candid
also
engin
produc
transgen
plant
nontox
domain
lf
fuse
cholera
toxin
b
subunit
ctb
produc
transgen
potato
kim
et
al
ctb
nontoxigen
pentamer
subunit
ct
highli
effici
carrier
mucos
antigen
deliveri
chemic
genet
coupl
antigen
act
via
bind
gangliosid
receptor
surfac
intestin
epitheli
cell
holmgren
et
al
facilit
uptak
conjug
stimul
antigen
present
mucos
immun
respons
ctb
express
transform
tobacco
chloroplast
confirm
form
pentam
share
biolog
activ
nativ
ctb
daniel
et
al
fusion
protein
synthes
potato
tuber
tissu
also
shown
assembl
pentam
could
bind
gangliosid
kim
et
al
immunogen
oral
administ
vaccin
candid
howev
evalu
increas
express
level
vaccin
antigen
chloroplast
transform
tobacco
plant
chebolu
daniel
pursu
use
optim
chloroplast
protein
express
condit
increas
express
compar
nuclear
transgen
tobacco
plant
achiev
aziz
et
al
pa
protein
exhibit
potent
cytotox
effect
macrophag
cell
line
vitro
presenc
lf
similar
transgen
b
juncea
gener
signific
serum
igg
iga
titr
follow
oral
administr
ct
adjuv
indic
develop
system
mucos
immun
respons
gorantala
et
al
furthermor
oral
immun
mice
demonstr
surviv
lethal
anthrax
challeng
gorantala
et
al
addit
pa
fragment
pa
domain
pa
div
also
express
tobacco
chloroplast
express
level
found
significantli
higher
compar
nuclear
transform
vs
total
solubl
protein
gorantala
et
al
intraperiton
oral
immun
total
solubl
protein
pa
div
transplastom
plant
elicit
antibodi
titr
similar
escherichia
pa
div
predominantli
subtyp
possess
activ
vitro
addit
intraperiton
oral
immun
pa
div
adjuv
alhydrogel
ct
respect
confer
protect
mice
lethal
anthrax
challeng
respect
compar
protect
adjuv
e
pa
div
evalu
mucos
respons
follow
oral
immun
detect
low
secretori
iga
titr
faecal
extract
mice
receiv
adjuv
e
pa
div
addit
div
antisera
enhanc
b
anthraci
spore
uptak
macrophag
vitro
suppress
spore
germin
gorantala
et
al
daniel
colleagu
success
introduc
pa
gene
chloroplast
genom
tobacco
plant
achiev
express
level
mg
per
gram
fresh
leaf
tissu
target
stabil
leav
crude
plant
extract
sever
month
cytotox
mous
macrophag
vitro
presenc
lf
watson
et
al
result
anim
studi
show
partial
purifi
adjuv
alhydrogel
induc
igg
titr
confer
protect
mice
intraperiton
letx
challeng
follow
subcutan
immun
similar
result
observ
purifi
pa
b
anthraci
suggest
pa
properli
fold
fulli
function
koya
et
al
calcul
demonstr
one
acr
transplastom
tobacco
plant
produc
million
dose
anthrax
pa
vaccin
koya
et
al
altern
approach
base
develop
anthrax
subunit
vaccin
parenter
administr
vaccin
candid
produc
plant
via
transient
express
exampl
anthrax
subunit
vaccin
candid
design
chichest
et
al
compris
domain
pa
domain
lf
separ
fuse
carrier
lickm
modifi
lichenas
clostridium
thermocellum
musiychuk
et
al
vaccin
express
agroinfiltr
nicotiana
benthamiana
plant
use
previous
describ
tobacco
mosaic
viru
tmv
hybrid
vector
musiychuk
et
al
shoji
et
al
mice
immun
dual
anthrax
vaccin
candid
adjuv
complet
incomplet
freund
adjuv
develop
high
titr
well
antibodi
chichest
et
al
use
express
system
anthrax
vaccin
candid
subsequ
produc
n
benthamiana
plant
compris
nonfus
glycosyl
recombin
chichest
et
al
new
vaccin
elicit
high
titr
antibodi
mice
rabbit
two
administr
presenc
alhydrogel
furthermor
rabbit
receiv
adjuv
complet
protect
lethal
aerosol
b
anthraci
challeng
vaccin
antigen
formul
alhydrogel
found
stabl
retain
immunogen
storag
suitabl
clinic
use
safeti
immunogen
healthi
adult
age
year
current
evalu
phase
clinic
trial
http
immunogen
vaccin
candid
assess
chang
serum
antibodi
titr
baselin
three
intramuscular
immun
four
dose
level
presenc
alhydrogel
nativ
pa
b
anthraci
glycoprotein
contain
potenti
glycosyl
site
glycosyl
recombin
pa
express
eukaryot
system
may
neg
affect
biolog
activ
antigen
exampl
abl
combin
lf
form
letx
induc
cell
death
vitro
mamedov
chichest
ja
jone
rm
ghosh
coffin
mv
herschbach
k
prokhnevski
ai
streatfield
sj
yusibov
v
prepar
elimin
neg
impact
aberr
glycosyl
nonglycosyl
version
produc
n
benthamiana
plant
bacteri
f
pngase
f
previous
strategi
proven
effici
pngase
f
result
vivo
deglycosyl
sexual
stage
antigen
p
falciparum
n
benthamiana
plant
mamedov
et
al
planta
deglycosyl
regain
abil
form
letx
vitro
induc
significantli
higher
level
antibodi
respons
mice
compar
glycosyl
besid
solubl
monomer
subunit
vaccin
anthrax
vaccin
candid
also
produc
plant
exampl
genet
fusion
acid
epitop
domain
pa
alfalfa
mosaic
viru
coat
protein
almv
cp
introduct
construct
strain
nicotiana
tabacum
cv
samsun
nn
plant
express
almv
replicas
gene
result
high
yield
fusion
protein
assembl
chimer
vlp
brodzik
et
al
two
intraperiton
immun
mice
purifi
recombin
vlp
presenc
complet
first
immun
incomplet
second
immun
freund
adjuv
elicit
serum
antibodi
react
pa
howev
detect
antibodi
respons
observ
two
five
immun
mice
anoth
studi
group
hepat
b
core
protein
hbcag
carri
express
transgen
n
tabacum
cv
plant
bandurska
et
al
electron
microscopi
detect
format
vlp
recombin
chimer
protein
contrast
unconjug
hbcag
immunogen
purifi
protein
mice
evalu
follow
three
intramuscular
inject
presenc
adjuv
combin
cpg
oligodeoxynucleotid
alhydrogel
analysi
immun
mous
sera
demonstr
presenc
signific
igg
titr
predominantli
subtyp
consist
serum
igg
profil
mice
immun
bandurska
et
al
neither
almv
vaccin
candid
assess
protect
efficaci
plant
transient
express
approach
also
util
produc
protect
monoclon
antibodi
anthrax
pa
exampl
human
monoclon
antibodi
produc
n
benthamiana
plant
activ
demonstr
vitro
vivo
compar
monoclon
antibodi
hull
et
al
subsequ
studi
glycosyl
nonglycosyl
pang
version
monoclon
antibodi
produc
n
benthamiana
plant
mett
et
al
glycosyl
monoclon
antibodi
pang
monoclon
antibodi
neutral
anthrax
letx
activ
vitro
protect
mice
intraperiton
challeng
spore
b
anthraci
stern
strain
surviv
respect
test
nonhuman
primat
nhp
pang
monoclon
antibodi
superior
glycosyl
monoclon
antibodi
exhibit
significantli
longer
termin
protect
vs
protect
glycosyl
monoclon
antibodi
challeng
lethal
dose
aerosol
anthrax
spore
data
demonstr
potenti
pang
monoclon
antibodi
therapi
treatment
inhal
anthrax
plagu
caus
major
pandem
epidem
throughout
human
histori
caus
categori
intracellular
bacterium
pesti
whose
life
cycl
includ
flea
small
mammal
primarili
rodent
http
wwwniaidnihgovtopicsplagu
numer
data
suggest
pesti
recent
evolv
enter
bacterium
yersinia
pseudotuberculosi
adapt
insect
vector
flea
transmiss
mammalian
host
via
subcutan
pneumon
rout
common
rout
bacteri
transmiss
anim
anim
bite
infect
flea
flea
ingest
blood
contain
pesti
rodent
host
bacterium
multipli
flea
gut
result
blood
clot
proventriculu
block
food
blood
passag
oesophagu
midgut
feed
block
flea
regurgit
infect
blood
bloodstream
mammal
transmit
bacterium
next
host
prentic
rahalison
transmiss
pathogen
human
may
occur
flea
bite
contact
fluid
infect
anim
aspir
respiratori
droplet
infect
anim
individu
pneumon
lesion
depend
bacterium
enter
bodi
plagu
manifest
three
clinic
form
bubon
common
form
natur
occur
plagu
septicaem
pneumon
pneumon
plagu
virul
fatal
form
diseas
cobb
chansolm
inglesbi
et
al
perri
fetherston
http
wwwniaidnihgovtopicsplagu
pesti
vaccin
plagu
plagu
vaccin
licens
unit
state
effect
pneumon
plagu
manufactur
discontinu
titbal
williamson
subunit
vaccin
plagu
base
two
pesti
antigen
either
express
individu
combin
produc
fusion
protein
antiphagocyt
fraction
capsular
envelop
glycoprotein
low
calcium
respons
virul
protein
lcrv
prentic
rahalison
fusion
protein
oral
administ
plagu
subunit
vaccin
candid
produc
gener
transgen
plant
tomato
alvarez
et
al
lettuc
et
al
carrot
tap
root
et
al
immunogen
follow
either
oral
subcutan
administr
evalu
exampl
mice
subcutan
prime
oral
boost
sever
dose
transgen
tomato
fruit
along
bacteri
ct
adjuv
immun
mice
shown
gener
serum
igg
intestin
iga
alvarez
et
al
immun
mice
subcutan
challeng
dose
pesti
protect
observ
anim
compar
mice
boost
nontransgen
tomato
alvarez
cardineau
author
explain
observ
medium
level
mous
protect
extend
time
interv
allow
last
vaccin
boost
bacteri
challeng
month
accord
previou
report
fujihashi
et
al
may
result
reduc
abil
age
mice
elicit
system
mucos
immun
respons
hand
result
indic
protect
pesti
maintain
long
term
level
target
accumul
origin
obtain
transgen
tomato
tissu
high
total
solubl
protein
alvarez
et
al
howev
subsequ
increas
total
solubl
protein
mean
suppress
target
gene
silenc
alvarez
et
al
subcutan
immun
mice
total
protein
extract
transgen
lettuc
adsorb
alhydrogel
also
elicit
signific
level
specif
serum
igg
although
express
level
low
total
solubl
protein
et
al
similarli
three
subcutan
inject
mice
solubl
protein
extract
transgen
carrot
tap
root
elicit
consider
level
serum
igg
et
al
three
transgen
plagu
subunit
vaccin
candid
predomin
igg
isotyp
produc
indic
immun
respons
alvarez
et
al
et
al
protect
efficaci
plagu
vaccin
candid
report
also
express
transform
tobacco
chloroplast
achiev
total
solubl
protein
arlen
et
al
crude
extract
transplastom
tobacco
leav
lyophil
enrich
anim
immunogen
studi
mice
prime
subcutan
repeatedli
boost
oral
unadjuv
gener
substanti
titr
serum
igg
predominantli
isotyp
higher
mice
subcutan
boost
adjuv
serum
iga
titr
also
detect
mice
among
oral
boost
mice
protect
lethal
aerosol
pesti
challeng
compar
mice
subcutan
boost
indic
oral
booster
elicit
protect
immun
respons
arlen
et
al
protect
predominantli
correl
circul
r
rather
iga
antibodi
titr
r
arlen
et
al
exampl
transient
produc
plagu
subunit
vaccin
includ
lcrv
antigen
fusion
express
n
benthamiana
plant
use
deconstruct
vector
santi
et
al
vaccin
antigen
inject
subcutan
three
dose
guinea
pig
elicit
serum
igg
confer
signific
protect
aerosol
challeng
virul
pesti
day
postexposur
highest
surviv
rate
six
eight
anim
lcrv
vaccin
follow
vaccin
five
eight
anim
santi
et
al
plagu
antigen
weakli
activ
innat
immun
cell
human
monocyt
induc
antibodi
respons
similar
occur
pesti
infect
del
prete
et
al
lcrv
antigen
also
produc
n
benthamiana
plant
fusion
lickm
carrier
musiychuk
et
al
either
singl
mett
et
al
dual
chichest
et
al
three
subcutan
inject
combin
adjuv
alhydrogel
elicit
strong
serum
igg
iga
titr
confer
complet
protect
cynomolgu
macaqu
lethal
challeng
pesti
mett
et
al
similarli
adjuv
alhydrogel
quil
administ
subcutan
three
dose
induc
high
titr
serum
igg
predominantli
isotyp
lcrv
also
fulli
protect
cynomolgu
macaqu
lethal
challeng
aerosol
pesti
chichest
et
al
suggest
strong
potenti
vaccin
candid
pneumon
plagu
smallpox
disfigur
highli
contagi
infecti
diseas
affect
human
popul
sinc
ancient
time
caus
variola
viru
categori
pathogen
symptom
appear
day
infect
includ
fever
malais
headach
prostrat
sever
back
pain
sometim
abdomin
pain
vomit
two
three
day
later
bodi
temperatur
fall
rash
appear
primarili
face
hand
forearm
trunk
histor
mortal
ordinari
smallpox
approxim
transmiss
viru
occur
inhal
aerosol
droplet
infect
symptomat
peopl
due
global
immun
campaign
smallpox
declar
erad
routin
vaccin
stop
fenner
et
al
http
wwwniaidnihgovtopicssmallpox
risk
smallpox
occur
result
bioterror
consid
low
howev
group
scientist
medic
profession
work
smallpox
similar
virus
research
set
militari
personnel
still
requir
receiv
vaccin
follow
recommend
advisori
committe
immun
practic
nation
vaccin
advisori
committe
suffici
amount
smallpox
vaccin
dose
avail
vaccin
everi
person
unit
state
need
licens
smallpox
vaccin
base
live
vaccinia
viru
highli
effect
http
wwwbtcdcgovagentsmallpoxprepcdcprepasp
http
wwwbtcdcgovagentsmallpoxvaccinationfactsasp
smallpox
subunit
vaccin
develop
reli
sever
orthopoxviru
antigen
elicit
neutral
antibodi
respons
exampl
protein
extracellular
envelop
vaccinia
viru
main
target
neutral
antibodi
present
vaccinia
immun
human
bell
et
al
furthermor
potent
induc
immun
respons
shown
protect
mice
nhp
poxviru
infect
benhnia
et
al
buchman
et
al
full
extracellular
antigen
domain
amino
acid
protein
produc
solubl
insolubl
form
transient
stabl
express
plant
golovkin
et
al
transient
express
n
benthamiana
base
gleba
et
al
result
rapid
product
solubl
high
yield
nuclear
transform
tobacco
collard
result
stabl
product
solubl
insolubl
form
respect
author
observ
major
differ
immunogen
depend
protein
solubl
rout
administr
mice
immun
via
oral
intranas
parenter
rout
oral
immun
anim
receiv
fresh
collard
leav
lyophil
powder
leaf
pellet
without
ct
mucos
adjuv
mouth
purifi
ct
gavag
igg
titr
detect
mous
sera
even
presenc
ct
adjuv
despit
presenc
system
intestin
antibodi
intranas
immun
mice
administ
three
dose
purifi
without
ct
adjuv
presenc
ct
purifi
elicit
serum
igg
parenter
immun
purifi
perform
two
subcutan
inject
freund
adjuv
one
intraperiton
inject
without
adjuv
result
highest
igg
titr
furthermor
purifi
given
mice
three
intramuscular
inject
presenc
cpgalum
adjuv
combin
induc
serum
igg
titr
reduc
vaccinia
viru
spread
comet
inhibit
assay
confer
protect
lethal
challeng
vaccinia
viru
golovkin
et
al
subsequ
studi
author
confirm
effici
intranas
vaccin
purifi
adjuv
ct
demonstr
sixfold
higher
dose
could
elicit
system
igg
titr
compar
induc
intramuscular
vaccin
contrast
intramuscular
immun
intranas
vaccin
induc
serum
igg
also
iga
respiratori
tract
dose
depend
analysi
igg
isotyp
demonstr
balanc
respons
essenti
protect
vaccinia
viru
matsui
et
al
read
smith
intramuscular
intranas
vaccin
contamin
purifi
increas
amount
total
solubl
protein
tobacco
plant
decreas
antibodi
respons
especi
induc
intranas
immun
shift
toward
type
taken
togeth
data
indic
import
antigen
dose
puriti
effici
intranas
vaccin
portocarrero
et
al
sever
vaccinia
viru
antigen
includ
express
transplastom
tobacco
plant
howev
immunogen
studi
antigen
report
rigano
et
al
b
ebola
viru
categori
pathogen
current
investig
therapi
ebola
target
major
virul
factor
ebola
viru
ebov
gp
transmembran
molecul
mediat
viru
host
cell
entri
cytopath
viral
effect
within
cell
lee
et
al
simmon
et
al
induc
protect
antibodi
wilson
et
al
far
therapi
advanc
ebola
treatment
option
monoclon
antibodi
cocktail
consist
human
chimer
monoclon
antibodi
latter
two
viru
neutral
produc
mapp
biophamaceut
inc
san
diego
ca
glycoengin
n
benthamiana
line
doubl
knockout
glycosyl
mutant
lack
xylos
core
fucos
residu
strasser
et
al
zeitlin
et
al
use
magnifect
gleba
et
al
administ
rhesu
macaqu
intraven
h
postinfect
follow
two
addit
dose
day
three
treat
monkey
protect
intramuscular
lethal
challeng
ebov
furthermor
partial
protect
four
six
monkey
treatment
given
h
postinfect
wherea
monkey
surviv
untreat
group
addit
three
time
potent
chines
hamster
ovari
recombin
counterpart
monoclon
antibodi
oling
et
al
differ
suggest
due
absenc
core
fucos
fc
region
monoclon
antibodi
lead
increas
antibodi
bind
fc
receptor
gamma
riii
enhanc
cellular
cytotox
compar
monoclon
antibodi
produc
chines
hamster
ovari
cell
zeitlin
et
al
base
result
author
suggest
cellular
cytotox
play
critic
role
protect
efficaci
confer
oling
et
al
treatment
began
confirm
ebola
infect
rhesu
macaqu
anim
still
surviv
challeng
pettitt
et
al
anoth
monoclon
antibodi
cocktail
zmab
consist
murin
neutral
monoclon
antibodi
qiu
et
al
show
promin
therapeut
efficaci
cynomolgu
macaqu
qiu
et
al
advanc
optim
monoclon
antibodi
composit
cocktail
consist
select
compon
zmab
human
produc
n
benthamiana
qiu
et
al
use
magnifect
gleba
et
al
zmapp
product
leafbio
san
diego
ca
joint
ventur
mapp
biopharmaceut
san
diego
ca
defyru
inc
toronto
canada
manufactur
cgmp
kentucki
bioprocess
plant
facil
http
http
wwwmappbiocom
http
wwwdefyruscomproductsebolazmabhtml
given
rhesu
macaqu
intraven
three
dose
day
apart
start
late
day
challeng
zmapp
revers
clinic
symptom
advanc
ebov
diseas
elev
liver
enzym
mucos
haemorrhag
rash
rescu
treat
anim
indic
promis
therapeut
efficaci
qiu
et
al
although
zmapp
safeti
previous
evalu
human
administ
sever
ebola
patient
investig
postexposur
therapi
ebola
outbreak
west
africa
seven
treat
patient
five
significantli
improv
recov
diseas
despit
initi
treatment
late
day
postinfect
http
mccarthi
lyon
et
al
random
phase
safeti
efficaci
clinic
trial
zmapp
put
investig
therapeut
treatment
patient
known
ebola
infect
invit
current
ongo
http
termzmapp
subject
also
recruit
phase
trial
assess
safeti
pharmacokinet
zmapp
follow
singl
administr
healthi
adult
volunt
age
dose
mgkg
http
termzmapp
despit
efficaci
zmapp
ebola
patient
suppli
limit
exhaust
provid
drug
suffici
quantiti
challeng
high
dose
zmapp
requir
optim
therapi
approxim
g
zmapp
three
administr
human
kg
weight
base
mgkg
dose
given
monkey
qiu
et
al
current
limit
capac
gmp
plant
product
rybicki
us
depart
health
human
servic
hh
sign
contract
mapp
biopharmaceut
acceler
drug
develop
mccarthi
sever
plant
biopharm
compani
also
gear
produc
zmapp
monoclon
antibodi
compon
exampl
medicago
quebec
canada
task
order
biomed
advanc
research
develop
author
barda
hh
part
indefinit
deliveryindefinit
quantiti
idiq
contract
medicago
defens
advanc
research
project
agenc
darpa
produc
three
viru
monoclon
antibodi
perform
compar
zmapp
studi
nhp
preliminari
result
shown
technolog
util
medicago
allow
rapidli
produc
antibodi
high
yield
therebi
potenti
boost
product
amount
worldwid
suppli
http
similarli
fraunhof
usa
center
molecular
biotechnolog
produc
viru
monoclon
antibodi
barda
addit
calib
biotherapeut
report
readi
produc
commerci
quantiti
zmapp
monoclon
antibodi
quickli
moor
transient
plant
express
strategi
also
appli
toward
product
antibodyantigen
vaccin
ebola
recombin
immun
fusion
complex
base
igg
antibodi
carri
fuse
phoolcharoen
et
al
previou
studi
tetanu
toxin
fragment
immun
complex
describ
report
bind
complement
factor
fc
receptor
gamma
riia
target
cell
immun
complex
inject
subcutan
without
adjuv
highli
immunogen
fulli
protect
mice
compar
commerci
antigen
adjuv
alum
contrast
nonadjuv
antigen
induc
protect
immun
chargelegu
et
al
produc
ebola
immun
complex
heavi
chain
hc
light
chain
lc
human
igg
monoclon
antibodi
direct
linear
epitop
ebola
subunit
genet
fuse
monoclon
antibodi
hc
transient
n
benthamiana
plant
phoolcharoen
et
al
use
previous
develop
bean
yellow
dwarf
geminivir
replicon
system
huang
et
al
due
interact
epitop
bind
site
recombin
hc
lc
assembl
chimer
igg
form
immun
complex
planta
capabl
bind
mice
subcutan
immun
four
dose
purifi
ebola
immun
complex
without
adjuv
elicit
viru
antibodi
product
level
compar
obtain
posit
control
vlp
phoolcharoen
et
al
base
recombin
rna
replicon
deriv
attenu
strain
venezuelan
equin
enceph
viru
pushko
et
al
studi
author
observ
administr
ebola
immun
complex
along
polyinosin
polycytidyl
acid
receptor
agonist
adjuv
elicit
robust
antibodi
respons
mice
compar
immun
complex
alon
furthermor
antibodi
protect
vaccin
mice
lethal
challeng
live
ebola
viru
correl
mix
humor
respons
antigen
phoolcharoen
et
al
overal
result
suggest
strong
potenti
ebola
immun
complex
vaccin
candid
ebola
apart
ebola
immun
complex
report
literatur
vaccin
candid
ebola
although
fraunhof
usa
center
molecular
biotechnolog
work
engin
ebola
vlp
subunit
vaccin
product
n
benthamiana
plant
dengu
viru
categori
pathogen
envelop
e
protein
dengu
viru
mediat
host
cell
receptor
bind
viral
entri
induc
neutral
antibodi
protect
immun
modi
et
al
staropoli
et
al
make
e
protein
major
target
dengu
subunit
vaccin
develop
sever
studi
report
product
e
subunit
vaccin
dengu
fever
exampl
domain
iii
diii
dengu
type
e
protein
amino
acid
transient
express
n
benthamiana
plant
use
vector
confirm
antibodi
bind
saejung
et
al
express
increas
incorpor
plant
signal
peptid
er
retent
sequenc
untransl
sequenc
locat
upstream
result
high
level
accumul
protein
total
solubl
protein
intramuscular
immun
mice
elicit
serum
igg
neutral
activ
dengu
type
viru
howev
immunogen
low
even
presenc
titermax
gold
adjuv
suggest
due
small
size
recombin
antigen
saejung
et
al
diii
amino
acid
also
produc
transgen
tobacco
plant
control
cauliflow
mosaic
viru
promot
antigen
total
solubl
protein
kim
et
al
fusion
ctb
total
solubl
protein
kim
et
al
despit
low
express
exhibit
bind
gangliosid
intestin
epitheli
cell
import
biolog
activ
altern
diii
fuse
intestin
peptid
ligand
increas
mucos
immunogen
fusion
express
transgen
rice
calli
control
induc
rice
amylas
promot
kim
et
al
fusion
protein
success
bound
cell
peyer
patch
confirm
vitro
vivo
antigen
uptak
assay
kim
et
al
immunogen
studi
dengu
subunit
vaccin
candid
perform
anoth
group
et
al
success
use
magnifect
system
gleba
et
al
transient
express
sever
version
e
protein
n
benthamiana
plant
truncat
e
protein
lack
membran
anchor
domain
et
amino
acid
polyprotein
consist
et
dengu
viru
structur
protein
c
prm
cprmet
amino
acid
fusion
hbcag
amino
acid
approach
target
success
express
approxim
mgg
fresh
leaf
weight
react
antibodi
although
cprmet
fulli
proteolyt
cleav
express
immunogen
recombin
protein
report
attempt
also
made
produc
dengu
subunit
vaccin
exampl
dengu
type
viru
premembran
e
polyprotein
prme
express
lettuc
chloroplast
vlp
assembl
confirm
transmiss
electron
microscopi
tem
kanagaraj
et
al
immunogen
vlp
report
recent
recombin
immun
approach
report
previous
ebola
phoolcharoen
et
al
appli
toward
dengu
vaccin
develop
recent
studi
hybrid
recombin
igg
base
monoclon
antibodi
design
chimer
consensu
diii
e
protein
display
ebola
epitop
fuse
hc
kim
et
al
author
transient
express
igg
molecul
n
benthamiana
plant
use
geminivir
vector
demonstr
format
immun
complex
could
bind
complement
factor
mice
immun
subcutan
immun
complex
adjuv
gener
potent
serum
igg
respons
superior
respons
observ
immun
diii
also
lack
adjuv
kim
et
al
result
show
potenti
diii
immun
complex
dengu
vaccin
candid
well
univers
potenti
platform
vaccin
develop
viral
infect
yellow
fever
viru
categori
c
pathogen
e
protein
yellow
fever
viru
yfe
play
multipl
role
cell
infect
kaufmann
rossmann
smit
et
al
stiasni
heinz
induc
antibodi
protect
immun
pierson
diamond
pierson
et
al
make
key
target
develop
subunit
vaccin
yellow
fever
et
al
recent
fraunhof
usa
center
molecular
biotechnolog
engin
express
yfe
n
benthamiana
tottey
shoji
jone
rm
chichest
ja
green
bj
musiychuk
k
shamloul
norikan
j
da
silva
frier
carid
ec
homma
cuber
r
streatfield
sj
yusibov
v
prepar
immunogen
challeng
studi
mice
nhp
underway
rift
valley
hanta
virus
categori
pathogen
recent
develop
subunit
vaccin
candid
haemorrhag
fever
cchf
compris
recombin
protein
gcgn
made
gc
gn
portion
cchf
viru
gp
ghiasi
et
al
gc
gn
previous
shown
contain
immunogen
epitop
capabl
induc
antibodi
ahm
et
al
gcgn
express
transgen
tobacco
hairi
root
cultur
leav
level
mgkg
mgkg
fresh
biomass
respect
evalu
immunogen
gcgn
subunit
vaccin
candid
mice
vaccin
use
follow
protocol
oral
administ
five
dose
transgen
leaf
hairi
root
pellet
interv
oral
administ
four
dose
transgen
leaf
hairi
root
pellet
interv
follow
singl
subcutan
boost
amount
total
solubl
protein
equival
gcgn
subcutan
four
dose
inactiv
cchfv
vaccin
interv
unvaccin
mice
receiv
mix
pellet
leav
root
group
vaccin
mice
develop
igg
titr
sera
iga
faec
indic
mucos
immun
respons
howev
mice
oral
immun
subcutan
boost
demonstr
signific
rise
igg
titr
compar
mice
oral
immun
gcgn
react
human
serum
igg
patient
recov
cchf
gener
result
suggest
potenti
gcgn
oral
administ
vaccin
cchf
howev
practic
administr
low
target
yield
need
address
prior
scale
product
anoth
studi
rift
valley
fever
subunit
vaccin
design
either
viru
nucleoprotein
n
truncat
gn
ectodomain
express
transgen
arabidopsi
thaliana
lagerqvist
target
select
base
potenti
stimul
antibodi
protect
lethal
viral
challeng
n
protein
accumul
transgen
plant
wherea
express
truncat
gn
detect
western
blot
nevertheless
antigen
feed
mice
transgen
plant
materi
result
elev
serum
igg
respons
second
dose
although
n
igg
titr
higher
truncat
gn
lower
singl
subcutan
inject
bacteri
deriv
n
protein
similarli
nucleocapsid
protein
hantaviru
serotyp
puumala
produc
transgen
tobacco
potato
plant
transgen
tobacco
leaf
extract
immunogen
administ
rabbit
intramuscularli
intraperiton
kehm
et
al
transgen
potato
tuber
leaf
powder
elicit
antibodi
respons
administ
mice
oral
khattak
et
al
west
nile
viru
wnv
flaviviru
categori
b
pathogen
commonli
transmit
human
bite
infect
mosquito
wnv
caus
febril
ill
enceph
mening
transmiss
wnv
document
europ
middl
east
africa
india
part
asia
australia
north
america
first
detect
sinc
spread
across
continent
unit
state
canada
http
wwwcdcgovwestnilefaqgenquestionshtml
current
vaccin
wnv
infect
http
wwwcdcgovwestnilefaqgenquestionshtml
domain
iii
diii
wnv
e
glycoprotein
contain
cell
motif
major
epitop
induc
strong
antibodi
protect
oliph
et
al
target
wnv
subunit
vaccin
develop
recent
diii
transient
produc
n
benthamiana
plant
use
magnifect
gleba
et
al
maximum
accumul
detect
day
postinfiltr
et
al
subcellular
local
test
diii
express
cytosol
er
chloroplast
target
accumul
highest
er
mgkg
fresh
leaf
tissu
diii
solubl
correct
conform
epitop
display
demonstr
specif
bind
monoclon
antibodi
recogn
nativ
wnv
diii
conform
epitop
subcutan
immun
mice
four
dose
purifi
diii
elicit
potent
serum
igg
titr
bound
nativ
form
viral
diii
antigen
exclus
isotyp
indic
immun
respons
et
al
import
wnv
protect
immun
previous
demonstr
fraction
human
immunoglobulin
result
indic
main
antibodi
isotyp
induc
follow
wnv
infect
contain
almost
entir
vitro
wnv
neutral
activ
confer
superior
protect
mice
compar
isotyp
unfraction
immunoglobulin
hofmeist
et
al
e
protein
wnv
also
express
chen
use
glycoengin
n
benthamiana
line
glycosyl
mutant
lack
glycan
residu
strasser
et
al
inclus
domain
di
dii
significantli
reduc
leaf
necrosi
increas
recombin
protein
accumul
mgkg
fresh
leaf
tissu
immun
mice
e
protein
presenc
alum
elicit
robust
neutral
antibodi
respons
specif
e
protein
diii
induc
cytokin
releas
igg
cytokin
predominantli
type
chen
addit
monomer
protein
subunit
vaccin
subunit
vaccin
wnv
also
engin
produc
infiltr
n
benthamiana
plant
magnicon
vector
gleba
et
al
encod
premembran
prm
e
protein
wnv
new
york
strain
result
transient
express
prm
matur
membran
e
protein
assembl
envelop
vlp
vlp
undergo
immunogen
test
mice
chen
chen
lai
chimer
nonenvelop
vlp
also
engin
diii
fuse
hbcag
fusion
antigen
transient
express
n
benthamiana
plant
use
either
geminivir
vector
magnicon
vector
yield
high
level
target
accumul
mgkg
versu
mgg
fresh
leaf
biomass
respect
chimer
vlp
strongli
immunogen
singl
dose
abl
elicit
potent
humor
cellular
immun
respons
mice
chen
chen
lai
chen
et
al
therapi
may
also
promis
approach
treatment
wnv
infect
sever
candid
produc
plant
use
magnicon
vector
giritch
et
al
geminivir
vector
huang
et
al
first
version
monoclon
antibodi
diii
wnv
e
protein
human
fulli
assembl
monoclon
antibodi
transient
produc
n
benthamiana
lettuc
respect
lai
et
al
high
level
target
accumul
leaf
tissu
mgkg
mgkg
fresh
biomass
n
benthamiana
lettuc
respect
lai
et
al
retain
antigen
bind
potent
activ
vitro
furthermor
singl
dose
protect
mice
lethal
challeng
wnv
prophylact
therapeut
set
even
given
late
day
infect
protect
efficaci
equival
achiev
mammalian
lai
et
al
effort
improv
monoclon
antibodi
efficaci
sever
modifi
version
monoclon
antibodi
also
engin
transient
express
n
benthamiana
includ
variabl
fragment
scfv
fuse
constant
domain
human
igg
hc
ch
tetraval
molecul
assembl
second
fuse
constant
domain
lc
cl
et
al
b
effici
express
assembl
plant
efficaci
exhibit
least
equival
vitro
neutral
vivo
mous
protect
compar
mammalian
studi
also
demonstr
differ
pattern
variant
suggest
proper
pair
hc
lc
essenti
complet
antibodi
differenti
glycosyl
result
differ
bind
variant
specif
fc
gamma
receptor
none
variant
show
enhanc
activ
vitro
indic
potenti
plant
produc
antibodi
molecul
minim
pathogen
reaction
patient
occur
result
gamma
receptor
interact
et
al
b
anoth
studi
lai
et
al
produc
target
carri
glycan
express
glycoengin
n
benthamiana
line
strasser
et
al
result
glycoengin
variant
exhibit
enhanc
wnv
neutral
vitro
equival
protect
mice
lethal
wnv
challeng
even
day
postinfect
parent
mous
monoclon
antibodi
two
glycoengin
variant
express
protect
efficaci
equival
indic
potenti
altern
lai
et
al
overal
data
demonstr
feasibl
produc
monoclon
therapi
improv
safeti
profil
japanes
enceph
je
zoonot
infect
caus
categori
c
flaviviru
observ
asia
western
pacif
transmit
human
via
bite
infect
mosquito
although
human
case
mild
small
percentag
infect
person
develop
enceph
approxim
mortal
rate
http
wwwcdcgovjapaneseenceph
vaccin
je
licens
unit
state
ixiaro
manufactur
intercel
livingston
uk
distribut
novarti
vaccin
diagnost
cambridg
inactiv
je
viru
jev
propag
vero
cell
cultur
approv
children
month
age
adult
vaccin
recommend
travel
asia
well
laboratori
worker
risk
exposur
jev
intercel
biomed
vaccin
safeti
remain
evalu
larger
human
popul
hill
et
al
similar
wnv
e
subunit
vaccin
candid
develop
jev
use
transgen
tobacco
appaiahgari
et
al
rice
wang
et
al
contrast
mammalian
cell
transgen
express
plant
could
occur
absenc
prm
protein
appaiahgari
et
al
target
express
leav
transgen
rice
reach
total
solubl
protein
protein
extract
e
protein
express
transgen
rice
shown
immunogen
mice
induc
strong
neutral
igg
titr
intraperiton
immun
system
mucos
antibodi
respons
oral
immun
wang
et
al
although
influenza
viru
classifi
categori
c
pathogen
remain
major
public
health
concern
reemerg
infect
unit
state
estim
annual
averag
death
result
respiratori
circulatori
caus
includ
pneumonia
influenza
rang
correspond
rang
death
per
person
cdc
annual
epidem
million
case
sever
influenza
ill
record
worldwid
result
death
http
addit
season
influenza
outbreak
occasion
influenza
pandem
aris
time
influenza
viru
contain
novel
ha
subtyp
emerg
spread
effici
among
human
novel
influenza
viru
swine
origin
emerg
infect
human
viru
tripl
reassort
gene
acquir
swine
avian
human
influenza
virus
garten
et
al
first
detect
peopl
unit
state
april
novel
influenza
viru
investig
team
et
al
spread
rapidli
across
globe
primarili
children
young
adult
popul
littl
serolog
immun
novel
ha
hancock
et
al
caus
world
health
organ
declar
pandem
june
http
nearli
confirm
case
countri
report
develop
sever
ill
often
rapid
progress
pneumonia
although
number
death
small
http
furthermor
highli
pathogen
avian
influenza
hpai
viru
spread
rapidli
onward
caus
seriou
poultri
outbreak
sever
asian
countri
europ
africa
also
abl
infect
human
among
individu
infect
virus
mortal
rate
http
wwwcdcgovfluavianfluindexhtm
http
wwwwhointinfluenzahumananimalinterfaceavianinfluenzaen
http
although
almost
report
human
case
close
contact
infect
bird
rare
instanc
presum
human
human
transmiss
consider
concern
human
health
remain
sever
human
case
also
viru
could
undergo
adapt
mutat
reassort
obtain
abil
spread
effici
among
human
http
wwwcdcgovfluavianfluindexhtm
http
wwwwhointinfluenzahumananimalinterfaceavianinfluenzaen
http
event
occur
andor
novel
virus
could
potenti
caus
pandem
exhibit
aggress
clinic
progress
devast
consequ
global
health
economi
influenza
infect
caus
envelop
rna
orthomyxovirus
b
c
type
lamb
krug
ruigrok
tradit
influenza
vaccin
manufactur
propag
influenza
virus
embryon
hen
egg
continu
chang
multipl
circul
epidem
strain
influenza
virus
lack
immun
emerg
virus
manufactur
new
upgrad
vaccin
requir
annual
basi
ha
abund
surfac
glycoprotein
influenza
viru
respons
bind
cell
surfac
receptor
intern
viru
play
key
role
viru
infect
pathogenesi
skehel
wiley
wilson
et
al
well
recogn
protect
provid
influenza
vaccin
mediat
primarili
highli
neutral
antibodi
han
marasco
make
ha
major
target
influenza
subunit
vaccin
develop
athmaram
et
al
cox
mischler
metcalf
wu
et
al
antibodi
inhibit
hemagglutin
activ
ha
hemagglutin
inhibit
hai
use
correl
protect
evalu
licens
influenza
vaccin
us
fda
tradit
influenza
vaccin
manufactur
use
embryon
hen
egg
form
inactiv
influenza
virus
gener
safe
efficaci
infect
matthew
osterholm
et
al
jone
exampl
sanofi
pasteur
swiftwat
pa
approv
trival
quadrival
vaccin
contain
influenza
b
strain
reformul
annual
influenza
season
given
one
two
dose
sanofi
pasteur
b
despit
tradit
influenza
vaccin
benefit
product
face
number
challeng
associ
depend
egg
suppli
potenti
viru
mutat
egg
adapt
skowronski
et
al
propag
live
virus
egg
allergen
challeng
would
potenti
overwhelm
pandem
progress
toward
develop
market
influenza
subunit
vaccin
mark
recent
approv
protein
scienc
meriden
ct
trival
season
influenza
vaccin
made
insect
cell
system
protein
scienc
corpor
mani
studi
report
develop
influenza
subunit
vaccin
review
chichest
et
al
daoust
et
al
redkiewicz
et
al
yusibov
et
al
regard
structur
three
type
influenza
subunit
vaccin
candid
produc
monomer
ha
trimer
ha
envelop
vlp
influenza
subunit
vaccin
candid
extens
studi
anim
model
shown
induc
protect
immun
daoust
et
al
landri
et
al
mett
et
al
shoji
et
al
subunit
vaccin
particularli
monomer
develop
fraunhof
center
molecular
biotechnolog
chichest
et
al
cum
et
al
vlp
season
strain
pandem
strain
influenza
develop
medicago
landri
et
al
ward
et
al
http
wwwclinicaltrialsgov
http
wwwmedicagocom
progress
clinic
trial
immunogen
safeti
well
effect
adjuv
evalu
healthi
human
volunt
tabl
review
yusibov
et
al
addit
subunit
vaccin
suscept
antigen
chang
ha
attempt
made
engin
univers
influenza
subunit
vaccin
use
influenza
viru
protein
evolv
slowli
ha
exampl
potato
viru
chimer
vlp
display
epitop
nucleoprotein
influenza
viru
strain
design
transient
produc
n
benthamiana
show
stimul
mhc
class
cell
mice
absenc
adjuv
lico
et
al
engin
vlp
display
ectodomain
epitop
protein
human
avian
influenza
virus
respect
transient
express
vigna
unguiculata
also
produc
meshcheryakova
et
al
due
poor
yield
weak
anim
immunogen
chimer
vlp
unlik
progress
clinic
develop
influenza
epitop
also
engin
fusion
human
papillomaviru
carrier
protein
express
n
benthamiana
use
vector
matic
et
al
immunogen
protect
efficaci
vaccin
candid
report
anoth
emerg
infect
rais
major
concern
sar
seriou
form
pneumonia
caus
sar
coronaviru
categori
c
pathogen
first
identifi
china
within
sever
month
sar
quickli
spread
around
world
infect
estim
peopl
death
often
requir
hospit
breath
assist
viru
spread
inhal
touch
sneez
cough
droplet
infect
person
http
mcintosh
perlman
identifi
sar
global
health
threat
issu
special
biosafeti
guidelin
handl
specimen
cultur
http
wwwwhointcsrsarsen
sinc
report
case
sar
http
wwwcdcgovsar
current
vaccin
sar
http
wwwwhointimmunizationtopicssarsen
spike
glycoprotein
cov
known
major
induc
antibodi
respons
protect
antivir
immun
callebaut
et
al
torr
et
al
furthermor
truncat
version
protein
shown
contain
import
antigen
domain
babcock
et
al
therefor
truncat
version
protein
target
subunit
vaccin
develop
sar
infect
yang
et
al
sever
report
product
subunit
vaccin
plant
one
studi
fragment
protein
express
transgen
tomato
tobacco
evalu
potenti
oral
administ
vaccin
pogrebnyak
et
al
singl
oral
administr
feed
lyophil
transgen
tomato
fruit
intragastr
deliveri
reconstitut
lyophil
transgen
tobacco
root
materi
induc
secret
mucos
iga
mice
detect
faecal
pellet
extract
lower
immunogen
transgen
tobacco
may
due
lower
amount
materi
administ
mice
smaller
dose
antigen
shorter
time
mucos
exposur
antigen
compar
transgen
tomato
effect
parenter
booster
immun
immunogen
protein
also
studi
intraperiton
boost
commerci
protein
peptid
follow
three
intragastr
immun
transgen
tobacco
root
materi
elicit
serum
igg
respons
contrast
boost
follow
parenter
immun
mice
transgen
tobacco
root
materi
two
time
subcutan
freund
adjuv
one
time
intraperiton
without
adjuv
induc
develop
system
immun
respons
elicit
serum
igg
titr
predominantli
isotyp
respons
magnitud
equival
secondari
immun
respons
elicit
commerci
peptid
adjuv
complet
freund
adjuv
pogrebnyak
et
al
anoth
preliminari
studi
partial
protein
produc
transgen
tobacco
lettuc
plant
transplastom
tobacco
plant
transient
express
tobacco
plant
li
et
al
howev
immunogen
report
acid
fragment
protein
domain
rbd
fuse
ctb
also
stabli
express
tobacco
chloroplast
facilit
mucos
immun
follow
oral
deliveri
vaccin
candid
fusion
protein
express
mostli
solubl
monomer
form
highest
express
total
solubl
protein
obtain
matur
transplastom
leav
zhong
et
al
immunogen
report
addit
protein
nucleocapsid
n
protein
also
assess
potenti
vaccin
target
molecul
transient
express
n
benthamiana
level
mgkg
fresh
leaf
weight
day
postinfiltr
zheng
et
al
mice
inject
intraperiton
pretreat
plant
extract
emulsifi
freund
adjuv
develop
strong
n
serum
igg
titr
follow
three
immun
includ
isotyp
addit
splenocyt
differ
time
point
indic
n
protein
induc
humor
cellular
immun
respons
zheng
et
al
altern
adjuv
suitabl
use
human
need
develop
vaccin
candid
addit
vaccin
antivir
compound
may
promis
countermeasur
viral
infect
exampl
griffithsin
lectin
red
alga
griffithsia
sp
antivir
activ
human
immunodefici
viru
hiv
bind
termin
mannos
residu
glycan
surfac
hiv
envelop
glycoprotein
block
viru
entri
host
cell
mori
et
al
due
structur
presenc
carbohydr
recognit
domain
format
dimer
et
al
griffithsin
may
broader
activ
inhibit
envelop
virus
display
similar
glycan
structur
exampl
recombin
griffithsin
shown
activ
jev
vitro
vivo
complet
protect
mice
lethal
viral
challeng
ishag
et
al
potenti
griffithsin
support
success
product
n
benthamiana
use
transient
express
approach
yield
mgkg
fresh
biomass
recov
puriti
okeef
et
al
griffithsin
exhibit
antivir
activ
broad
spectrum
coronavirus
includ
via
specif
bind
spike
glycoprotein
protein
okeef
et
al
efficaci
griffithsin
demonstr
use
lethal
mous
model
pulmonari
infect
intranas
treatment
griffithsin
protect
anim
sar
infect
mechan
cov
diseas
pathogenesi
believ
involv
excess
dysregul
cytokinechemokin
respons
cell
perlman
dandekar
result
current
studi
support
hypothesi
treatment
griffithsin
significantli
reduc
product
sever
cytokin
mous
lung
tissu
includ
day
postinfect
compar
result
untreat
infect
mice
okeef
et
al
anoth
lectin
actinohivin
actinomycet
inokoshi
et
al
produc
n
benthamiana
use
vector
shown
activ
hiv
syncytium
format
vitro
assay
matoba
et
al
version
recombin
fusion
actinohivin
fc
portion
human
monoclon
antibodi
recent
report
exhibit
nanomolar
antivir
activ
hiv
well
envelop
virus
includ
influenza
viru
hepat
c
viru
ebola
viru
suggest
clinic
diagnost
applic
hybrid
polypeptid
matoba
botulinum
neurotoxin
lethal
natur
occur
toxin
categori
agent
produc
anaerob
bacterium
clostridium
botulinum
caus
botul
rare
seriou
diseas
http
wwwniaidnihgovtopicsbotul
http
arnon
et
al
montecucco
treatment
botul
includ
administr
antitoxin
soon
possibl
establish
clinic
diagnosi
http
wwwniaidnihgovtopicsbotul
arnon
et
al
montecucco
us
fda
approv
use
antitoxin
neutral
seven
known
botulinum
neurotoxin
serotyp
us
fda
vaccin
botul
investig
pentaval
abcd
botulinum
toxoid
vaccin
worker
risk
occup
exposur
botulinum
toxin
develop
sever
decad
ago
due
decreas
immunogen
increas
reactogen
vaccin
stock
discontinu
cdc
attempt
develop
subunit
vaccin
botul
mucoric
express
system
product
mucos
vaccin
nochi
et
al
yuki
et
al
combin
rnai
technolog
suppress
accumul
major
rice
endogen
storag
protein
produc
botul
vaccin
antigen
rice
seed
use
system
half
hc
botulinum
type
neurotoxin
bohc
express
rice
averag
mg
per
seed
yuki
et
al
target
water
solubl
accumul
cytoplasm
protein
bodi
ii
rice
seed
mucos
intranas
immun
mice
confer
protect
lethal
challeng
botulinum
type
neurotoxin
intranas
administ
presenc
ct
nontox
chimer
adjuv
mctaltb
combin
subunit
mutant
ct
pentamer
b
subunit
enterotoxin
enterotoxigen
e
coli
high
level
serum
igg
nasal
iga
respons
induc
immun
mice
surviv
challeng
yuki
et
al
antibotulinum
toxin
scfv
recombin
monoclon
antibodi
also
produc
plant
function
activ
antibodi
produc
transgen
tobacco
demonstr
vitro
use
mous
muscl
twitch
assay
almquist
et
al
base
effici
scfv
captur
process
dose
requir
provid
antidot
human
author
calcul
ha
transgen
tobacco
could
yield
kg
scfv
would
allow
product
therapeut
dose
mg
botulinum
toxin
antibodi
oligoclon
cocktail
averag
kg
person
blood
volum
l
almquist
et
al
indic
potenti
product
system
antibotulinum
scfv
manufactur
ricin
toxin
ricinu
communi
castor
bean
plant
categori
b
agent
ricin
easi
extract
stabl
highli
toxic
rapid
irrevers
action
symptom
ricin
poison
time
death
depend
rout
exposur
inhal
ingest
inject
dose
receiv
toxin
affect
mani
organ
ricin
poison
symptomat
treat
support
medic
care
http
wwwbtcdcgovagentricinfactsasp
et
al
recombin
thermost
vaccin
candid
ricin
soligenix
princeton
nj
current
develop
mice
intramuscular
immun
rivax
protect
challeng
ricin
deliv
gavag
inhal
smallshaw
et
al
nhp
model
rivax
confer
protect
lethal
inhal
challeng
aerosol
ricin
roy
et
al
addit
countermeasur
ricin
intox
develop
base
monoclon
antibodi
recogn
immunodomin
linear
neutral
epitop
amino
acid
tlarsfiiciqm
subunit
ricin
toxin
demonstr
efficaci
vitro
vivo
neal
et
al
vitro
use
vero
cytotox
assay
murin
shown
bind
ricin
holotoxin
high
affin
dissoci
constant
neutral
inhibitori
concentr
vivo
passiv
administr
intraperiton
inject
via
backpack
tumour
protect
mice
system
intraperiton
mucos
intragastr
ricin
challeng
respect
neal
et
al
base
properti
murin
monoclon
antibodi
engin
version
monoclon
antibodi
produc
plant
version
chimer
deriv
murin
hc
lc
variabl
region
fuse
human
framework
engin
transient
express
n
benthamiana
ohara
et
al
demonstr
epitop
specif
ricin
neutral
activ
similar
nativ
murin
monoclon
antibodi
passiv
administr
intraperiton
inject
protect
mice
system
ricin
challeng
assess
efficaci
monoclon
antibodi
postricin
exposur
administ
h
toxin
challeng
shown
rescu
mice
death
thu
potenti
prophylact
therapeut
treatment
ricin
intox
recent
emerg
reemerg
infecti
diseas
well
risk
bioterror
attack
pose
major
threat
public
health
challeng
effect
current
prophylact
therapeut
countermeasur
wherea
vaccin
mainstay
infecti
diseas
prophylaxi
tradit
vaccin
fail
satisfi
global
demand
limit
scalabl
product
system
long
product
timelin
product
safeti
concern
similar
issu
applic
therapeut
antibodi
agent
concern
may
address
develop
safe
scalabl
subunit
vaccin
monoclon
antibodi
recombin
therapeut
protein
past
decad
subunit
vaccin
monoclon
antibodi
antivir
rang
emerg
reemerg
pathogen
produc
differ
plant
express
system
evalu
preclin
clinic
studi
recent
year
mark
improv
level
target
express
yield
puriti
reproduc
construct
facil
capabl
produc
materi
cgmp
clinic
trial
commerci
use
improv
yield
efficaci
candid
countermeasur
suggest
feasibl
use
product
fight
diseas
howev
differ
number
preclin
studi
summar
tabl
clinic
trial
summar
tabl
conduct
candid
countermeasur
consider
partli
reflect
normal
narrow
potenti
product
candid
preclin
clinic
studi
also
reflect
fact
mani
preclin
studi
investig
necessarili
target
clinic
howev
increas
momentum
advanc
lead
candid
clinic
recent
year
regulatori
commerci
landscap
start
chang
favour
subunit
vaccin
monoclon
antibodi
therapeut
protein
human
use
exemplifi
licens
commerci
releas
taligluceras
alfa
howev
approv
commerci
candid
regulatori
author
consid
safeti
efficaci
also
addit
factor
includ
effect
dose
number
requir
dose
product
stabil
storag
addit
subunit
vaccin
requir
adjuv
other
particl
may
efficaci
alon
factor
would
reflect
ultim
product
cost
regard
product
stabil
subunit
vaccin
therapeut
protein
deliv
via
oral
rout
may
undergo
rapid
degrad
gastrointestin
tract
stress
need
protect
formul
addit
achiev
rapid
clinic
develop
countermeasur
downstream
process
protein
purif
approach
need
develop
manufactur
target
larg
scale
although
facil
built
north
america
europ
consider
valid
qualif
effort
need
undertaken
bring
onlin
commerci
product
author
conflict
interest
declar
